BASF SE and Poietis SAS have signed a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal is to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications.
The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows a precise positioning of skin cells in three-dimensional structures. Thus, it is now possible to produce fully printed skin equivalents in only two weeks to further study active ingredients effectiveness.
In the coming years, BASF intends to develop and market several active ingredients for cosmetic products that harness the findings of the collaboration. At this year's Cosmetagora, Dermagenist led the way being BASF’s first active ingredient whose efficacy has been confirmed by using laser-assisted bioprinted skin models.
“Bio-printed 3D models are the method of choice for the predictive evaluation of ingredients as these models reproduce the cell environment in vitro by having mechanical and metabolic functionalities close to the vivo,” said Fabien Guillemot, founder and president of Poietis.
BASF SE and Poietis SAS have signed a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal is to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications.
The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows a precise positioning of skin cells in three-dimensional structures. Thus, it is now possible to produce fully printed skin equivalents in only two weeks to further study active ingredients effectiveness.
In the coming years, BASF intends to develop and market several active ingredients for cosmetic products that harness the findings of the collaboration. At this year's Cosmetagora, Dermagenist led the way being BASF’s first active ingredient whose efficacy has been confirmed by using laser-assisted bioprinted skin models.
“Bio-printed 3D models are the method of choice for the predictive evaluation of ingredients as these models reproduce the cell environment in vitro by having mechanical and metabolic functionalities close to the vivo,” said Fabien Guillemot, founder and president of Poietis.
No comments:
Post a Comment